Measurement of anti-Treponema pallidum body fluid antibodies using a mixture of Treponema pallidum surface antigens

JP2023030143A5Active Publication Date: 2024-11-13SETEKA CORP
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2022208292
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Filing Date
2022-12-26
Publication Date
2024-11-13
Estimated Expiration
2041-06-07

AI Technical Summary

Technical Problem

Current methods for diagnosing syphilis using Treponema pallidum antigens face challenges in stability, scalability, and animal welfare concerns, necessitating improved sensitivity in detecting anti-TP antibodies in body fluids.

Method used

A mixture of recombinant TpN47 and TpN15-TpN17 antigens derived from genetically modified silkworms is used for enhanced sensitivity in immunological assays, leveraging gene amplification and expression techniques to produce these antigens in silkworms, which are then extracted and used in various immunological measurement methods.

Benefits of technology

The method significantly improves the sensitivity of syphilis diagnosis, enabling early detection of anti-TP antibodies with higher accuracy and reliability compared to conventional methods.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

To provide a means for detecting infection with Treponema pallidum with higher sensitivity. [Solution] The inventors have discovered that by measuring anti-Treponema pallidum antibodies in body fluid samples by immunological assay using a mixture of TpN47 antigen derived from the cocoon thread or silk gland of genetically modified silkworms, which are artificial surface antigens of Treponema pallidum, and the same genetically modified TpN15-TpN17 fusion antigen, the measurement sensitivity is clearly improved to a practical level, even exceeding that of native Treponema pallidum antigens.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to a means for measuring a humoral antibody using a raw material obtained from a genetically modified organism. More specifically, the present invention relates to a means for measuring a humoral antibody against syphilis using a mixture of Treponema pallidum surface antigens derived from genetically modified silkworms.

Background Art

[0002] Syphilis is a representative sexually transmitted disease that has existed for a long time and has been increasing rapidly in recent years. Until around 1999 - 2012, the number of reported cases was about 600 - 800 per year, and except for a very small number of medical staff, it was a disease that was not much noticed in daily medical practice. However, after exceeding 1228 cases and 1000 cases in 2013, it has continued to increase steadily, exceeding 7000 cases in 2018. The preliminary value as of the 46th week of 2019 was 5817 cases, and it cannot yet be said that the downward trend has turned.

[0003] Syphilis is a chronic infectious disease that spreads from local to systemic caused by Treponema pallidum (hereinafter referred to as Treponema syphilis or TP). The first - stage syphilis rash occurs at the infection site, and then the second - stage syphilis rash occurs systemically. Both the first - stage rash and the second - stage rash will naturally subside without treatment and become asymptomatic (latent syphilis), and it progresses while repeating symptom remission and exacerbation. It is said that late - stage symptoms (late syphilis) will appear several years after infection. Even if a person is infected with syphilis, not all patients will develop symptomatic syphilis, and among those with clinical symptoms, especially those who have not received treatment, there is a period when they will become asymptomatic syphilis. Currently, although it can be sufficiently treated with antibiotics, due to the co - existence of such asymptomatic states, serological tests are becoming the mainstream rather than obtaining specimens from the affected area.

[0004] One such diagnostic method for syphilis involves detecting antibodies produced in the patient's bodily fluids (humeral antibodies). In this antibody detection method, Treponema pallidum bacteria have been cultured in rabbit testes, solubilized and extracted with surfactants, and then various methods have been used to remove insoluble matter and purify necessary components to produce the antigen. However, because this method uses rabbits to produce the antigen, it has been difficult to obtain large quantities of stable antigens of consistent quality. Furthermore, it has also been viewed as problematic from an animal welfare perspective. To address these issues, in recent years, a method has been developed that uses Treponema pallidum surface antigen (TP antigen) produced in E. coli using genetic engineering technology (Patent Document 1, Non-Patent Document 1).

[0005] On the other hand, recently, a technology has been established to produce useful proteins in silkworms (recombinant silkworms) using genetic engineering (Non-Patent Documents 2, 3, 4, 5). [Prior art documents] [Patent Documents]

[0006] [Patent Document 1] Japanese Patent Application Publication No. 11-192089 [Non-patent literature]

[0007] [Non-Patent Document 1] V.Sambri,et al.,Western Immunoblotting with Five Treponema pallidum Recombinant Antigens for Serologic Diagnosis of Syphilis Clin.Diagno.Labo.Immuno.,8(3) p.534-539(2001) [Non-Patent Document 2] Molecular Entomology, pp. 36-45, Kyoritsu Shuppan [Non-Patent Document 3] Dev. Growth Differ., 56, 14-25, 2011 [Non-Patent Document 4] J. Biotechnol. Biomater, S9, 004, 2012 [Non-Patent Document 5] Targeted Gene Expression Using the GAL4 / UAS System in the Silkworm Bombyx mori Morikazu Imamura, etal. Genetics, 165, 1329- 1340 (2003) [Disclosure of the Invention] [Problems that the invention aims to solve]

[0008] As mentioned above, while syphilis is currently treatable with antibiotics, asymptomatic cases often coexist. Therefore, there remains a high need to diagnose the infection as accurately as possible and to make decisions regarding early treatment. This necessitates the provision of methods to detect infection by Treponema pallidum with higher sensitivity. In this regard, it is necessary to further improve the sensitivity performance of the currently available recombinant TP antigen used to measure anti-TP antibodies in bodily fluid samples. [Means for solving the problem]

[0009] The inventors of the present invention conducted studies to solve the above problems. They found that by using a mixture of TpN47 antigen and TpN15-TpN17 fusion antigen derived from the silk or silk gland of genetically modified silkworms, which are artificial surface antigens of TP, and measuring anti-TP antibodies in body fluid samples using an immunoassay method, the measurement sensitivity was significantly improved to a practical level, even exceeding that of native TP antigens.

[0010] (1) Outline of the present invention In other words, the present invention provides a method for measuring body fluid antibodies (hereinafter also referred to as the measurement method of the present invention) by contacting a body fluid sample with a mixture of genetically modified TpN47 antigen (hereinafter also referred to as the 47 antigen), which is an artificial surface antigen of Treponema pallidum (TP), derived from the silk or silk gland of genetically modified silkworms transformed with the TpN47 gene (hereinafter also referred to as the 47 recombinant silkworm), and genetically modified TpN15-TpN17 fusion antigen (hereinafter also referred to as the 15-17 antigen), which is derived from the silk or silk gland of genetically modified silkworms transformed with a fusion gene of the TpN15 gene and the TpN17 gene (hereinafter also referred to as the 15-17 recombinant silkworm), and measuring the anti-Treponema syphilis antibody in the body fluid sample as a binding signal with the above antigen mixture using an immunological measurement method.

[0011] Silkworms transformed with the TP gene can be produced using already available technology. In this example, cocoons derived from recombinant 47 silkworms and 15-17 silkworms were purchased from a specialized company, and the silk threads from these cocoons were used as raw materials for the 47 antigen and the 15-17 antigen. However, to the best of the inventor's knowledge, the genetically modified TpN47 antigen and TpN15-TpN17 antigen obtained from these silk threads are not publicly known.

[0012] (2) Treponema pallidum (TP) TP is a type of spirochete, and several proteins have been reported as TP antigen proteins (The Journal of Immunology, Vol.129, p.833-838, 1982; The Journal of Immunology, Vol.129, p.1287-1291, 1982; Journal of Clinical Microbiology, Vol.21, p.82-87, 1985; Journal of Clinical Microbiology, Vol.30, p.115-122, 1992), TP As surface antigen proteins, TpN47 (molecular weight 47kd), TpN15 (molecular weight 15kd), and TpN17 (molecular weight 17kd) are known as representative TP surface antigen proteins, and their gene sequences, both nucleotide and amino acid sequences, have been determined (Microbiological. Reviews, Vol.57, p.750-779; Infection and Immunity, Vol.61, p.1202-1210, 1993; Journal of Bacteriology, Vol.162, p.1227-1237, 1992; Infection and Immunity, Vol.57, p.3708-3714, 1989).

[0013] (3) Recombinant TP antigen <Gene cloning> Recombinant TpN47 antigen and recombinant TpN15-TpN17 fusion antigen obtained using genetically modified Escherichia coli are already known (Patent Document 1, etc.), and their production can be carried out by conventional methods in genetic engineering. That is, the target TpN47 gene or TpN15-TpN17 fusion gene is cloned, the DNA sequence encoding the obtained Tp antigen is incorporated into a vector, and then the vector is introduced into host Escherichia coli. Then, the transformed Escherichia coli is cultured, and the DNA sequence encoding the Tp antigen of the vector is expressed, making it possible to obtain large quantities of the two desired types of TP antigens. Furthermore, these E. coli-derived recombinant TP antigens are also commercially available. However, as mentioned above, to the best of the inventor's knowledge, recombinant TP antigens derived from silkworms are not publicly known.

[0014] The cloning of the above genes can be suitably carried out by gene amplification methods such as PCR and recombinant PCR, regardless of the host organism to which the gene is intended to be introduced, such as E. coli or silkworms (described later). Gene chemical synthesis can also be used as needed.

[0015] When using the PCR method, the desired TP antigen gene fragment can be obtained as a gene amplification product by specifically amplifying the TP antigen region of the native TP antigen gene using forward and reverse primers that sandwich the coding region of the TpN47 gene. The native TP antigen gene can be obtained by extracting genomic DNA from syphilis bacteria (Treponema pallidum, Nicols strain) cultured in rabbit testicles.

[0016] Recombinant PCR is suitably used to obtain a TpN15-TpN17 fusion gene. Specifically, the TpN15 gene and the TpN17 gene are obtained separately by gene amplification methods such as the PCR method described above. A complementary sequence is added to the end of one DNA fragment to which the other DNA fragment is to be bound. The two gene fragments are then mixed, and gene amplification is performed by PCR using primers complementary to both ends of the desired fusion gene, thereby obtaining the desired TpN15-TpN17 fusion gene fragment.

[0017] Here, regarding at least silkworms, examples of gene amplification primers used when cloning the TpN47 gene using the PCR method and when cloning the TpN15 - TpN17 fusion gene using recombinant PCR are provided. These examples can be easily derived by fitting each sequence of the TP antigen into the knowledge of known PCR methods or recombinant PCR methods. Regarding the gene amplification primers exemplified here, the underlined part of the base sequence is the terminal sequence of each gene. As in each example, it is preferable that a stop codon is added to the added sequence at the 3' end. Also, it is preferable that predetermined restriction enzyme recognition sites are provided in the 5' end sequence and the 3' end sequence. For example, the addition of a BamHI recognition sequence to the 5' end and the addition of a NotI recognition sequence to the 3' end sequence are exemplified, but it is not limited thereto. It can be freely selected according to the vector to be incorporated, such as the restriction enzyme sites in the binary expression system described later.

[0018] (a) When cloning the TpN47 gene using the PCR method, for the above TP genomic DNA, as primers for TpN47, for example; 47K primer 1: 5' end GATCC GGATCC GGCTCGTCTCATCATGAG (SEQ ID NO: 1), 47K primer 2: 3' end TAGCC GCGGCCGC CTA AGACACACGGGATAGGAC (SEQ ID NO: 2), are exemplified. Using these, the cloning of the TpN47 gene can be carried out.

[0019] (b) When cloning the TpN15 - TpN17 fusion gene using the recombinant PCR method, for the above TP genomic DNA, first, as primers for TpN17, for example; 17K primer 1: 5' end GATCC GGATCC TGTGTCTCGTGCACAACC (SEQ ID NO: 3), 17K primer 2: 3' end TAGCCGCGGCCGCCTA TTTCTTTGTTTTTTTGAGCAC (Sequence ID 4) These are examples. Using these, the TpN17 gene can be cloned.

[0020] Next, as a primer for TpN15, for example; 15K Primer 1: 5' end GATCC GGATCC TGTTCATTTAGTTCTATC (Sequence ID 5) 15K Primer 2: 3' end TAGCC GCGGCCGCCTA CCTGCTAATAATGGCTT (Sequence ID 6) Examples are given. Using these, the TpN15 gene can be cloned.

[0021] Then, using the TpN17 and TpN15 genes obtained as described above, the TpN15-TpN17 fusion gene can be cloned.

[0022] In other words, by appropriately co-administering these gene fragments with primers used for fragment fusion amplification and performing a PCR reaction, the desired TpN15-TpN17 fusion gene can be cloned. For example, consider the following: Firstly, as a primer for 15K fragment 1, Sequence ID 5 and the following Sequence ID 7 Pair of primers for amplification: Sequence ID 5 The 15K primer 1 at the 5' end, As a 17K-5' end + 15K-3' end primer, TGTGCACGAGACACACCTGCTAATAATGGCTTCCT (Sequence ID 7) Prepare the necessary materials and perform a PCR reaction using the TpN15 gene obtained above as a template to clone the 15K junction fragment; Secondly, as a primer for 17K fragment 2, the following Sequence ID 8 and Sequence ID 4 Pair of primers for amplification: 5' end TGTGTCTCGTGCACAACCGT (Sequence number 8) and, Sequence ID 4 17K primer 2 at the 3' end Prepare the necessary materials and perform a PCR reaction using the TpN17 gene obtained above as a template to clone the 17K junction fragment; Thirdly, as a primer for 15K-17K amplification, the above Sequence ID 4 and Sequence ID 5 Prepare a pair of amplification primers and obtain the first and second results above. 15K connected fragment and 17K connected fragment Perform a PCR reaction using the template; This allows for the cloning of the desired TpN15-TpN17 fusion gene.

[0023] The obtained TP antigen gene fragment can be incorporated into a plasmid vector using conventional methods such as ligation or linker ligation.

[0024] <Genetically modified silkworms> Genetically modified silkworms can be obtained by transforming silkworms with the TP antigen gene. The silkworm (Bombyx mori) has been used in sericulture for approximately 5,000 years, and is a wild species. The silkworm is a domesticated species derived from the Japanese silkworm (Bombys mandarina), and is a domesticated insect that has undergone continuous selective breeding. For silkworms, transformation methods are already available, and their entire genome information has also been revealed (Goldsmith, MR et al., Annu. Rev. Entomol., 50:71-100, 2005).

[0025] Typical transformation methods include those using transposons as vectors and binary expression systems. However, transformation can also be performed by knocking in the TP antigen gene using TALEN, CRISPR / CAS9, etc.

[0026] One well-known method using transposons is the plasmid vector using the transposon piggy Bac. This plasmid vector contains two inversely oriented repeat sequences at both ends of the piggy Bac transposon, and the TP antigen gene to be incorporated into the silkworm chromosome is inserted between these repeat sequences. When this is injected in small amounts into silkworm eggs along with a transposase expression helper plasmid, the TP antigen gene region between the repeat sequences is transferred by the action of the transposase, thus obtaining silkworms in which the TP antigen gene has been incorporated into the chromosome. When using Bac, there are limitations such as the fact that the TP antigen gene is inserted almost randomly into the TTAA base sequence in the silkworm genome, and that the size of the DNA fragment that can be inserted is limited to approximately 20kb or less.

[0027] Examples of binary expression systems include the GAL4 / UAS system, the IE1 / hr3 system, and the Tet-On / Off system. Of these, the GAL4 / UAS system has already been used in silkworms (M. Imamura et al., Genetics 165:1329-1340, 2003: Non-Patent Literature 5).

[0028] In the GAL4 / UAS system, a construct (trap construct) is created in which the GAL4 gene is placed under the basic promoter and incorporated into various genomic regions. When the incorporated trap construct is under the control of a certain enhancer, the basic promoter, such as the sericin 1 promoter, traps that enhancer, and GAL4, a yeast-derived transcription factor, is expressed. If the enhancer is active only in a specific group of silkworm cells, GAL4 is expressed only in that group. The sericin 1 promoter mentioned above functions in the expression of sericin 1 in the mid-silk gland of silkworms. Sericin 1 is the most abundant of the three types of sericin (sericin 1-3). When the TP antigen gene, the target of this invention, is expressed in the mid-silk gland of silkworms and the TP antigen is secreted into the sericin layer of the cocoon, sericin is water-soluble and can be dissolved in an aqueous solvent such as phosphate buffer, making it easy to extract the TP antigen and preserving its activity. For these reasons, the sericin 1 promoter described above is the most preferred basic promoter when applying the GAL4 / UAS system to the present invention. However, when the target gene, the TP antigen gene, is directly linked to the sericin 1 promoter, the expression level is insufficient, so it is preferable to use a binary expression system that enhances its expression. For example, when a construct in which the TP antigen gene is placed downstream of the UAS (upstream activator sequence), which is the recognition sequence of GAL4, is incorporated into the genome, the expressed GAL4 is activated by the recognition of the UAS, and the TP antigen gene is efficiently expressed.

[0029] This type of ectopic gene expression using the GAL4 / UAS system can be performed in silkworms that are double transgenic, obtained by crossing genetically modified silkworms that are GAL4 transgenic (drivers) with genetically modified silkworms that are UAS transgenic (effectors).

[0030] The IE1 / hr3 system utilizes the property of the IE1 transactivator and hr3 enhancer, both present in baculoviruses that infect insects, to control gene expression in the host insect, thereby increasing the expression level of the target gene, the TP antigen gene. IE1 expressed with a sericin 1 promoter activates hr3, thereby enhancing the expression level of the target protein, the TP antigen protein.

[0031] In the Tet-On / Off system, the tetracycline regulatory activator in E. coli activates the expression of the TP antigen gene, which is a transgene linked downstream of the transcriptional regulatory response element sequence. However, tetracycline or doxycycline binds to and inhibits the activator, so the expression of the TA antigen gene can be switched on or off by administering these drugs.

[0032] Confirmation of whether a target gene, such as the GAL4 gene or the TP antigen gene, has been introduced into a silkworm and is being expressed can be performed by introducing a marker gene downstream of the target gene, such as the GAL4 gene or the TP antigen gene. A fluorescent protein gene is preferably used as the marker gene. Two or more fluorescent protein genes of different colors can be used as needed. For example, if a red fluorescent protein gene is used as a marker for one group (e.g., driver silkworms) and a green fluorescent protein gene is used as a marker for the other group (effector silkworms), a yellow fluorescence (a combination of red and green) can be observed in silkworms that have been crossbred and introduced with both genes. This yellow fluorescence can then be used as an indicator to select silkworms that have been introduced with both the driver and effector genes.

[0033] (4) The TP antigen mixture of the present invention As described above, the TP antigen mixture of the present invention is a mixture of 47-antigen and 15-17 antigen. The mixing ratio of 47-antigen to 15-17 antigen is preferably 4:6-6:4 (mass ratio). The TP mixture of the present invention may be in the form of an aqueous composition dissolved in an aqueous solvent, a lyophilized product, or immobilized on a solid phase. The concentration of the TP antigen mixture of the present invention in the aqueous composition can be freely set according to the intended use of the mixture.

[0034] (5) Body fluid specimens The bodily fluid sample used in the measurement method of the present invention is not limited to any bodily fluid sample that may contain anti-TP antibodies due to syphilis infection. Examples include blood samples, saliva samples, and urine samples. Among these, blood samples are particularly preferred. Examples of blood samples include whole blood samples, serum samples, and plasma samples, with serum samples or plasma samples being even more preferred. If necessary, the addition of anticoagulants, etc., or serum obtained by absorption treatment of non-specific antibodies with the heated supernatant of TP Reiter strain culture medium is also acceptable. Dilution with physiological saline or buffer solution may also be performed as appropriate.

[0035] (6) Immunological measurement method The immunological measurement method used in the measurement method of the present invention is not limited to any means that can measure the anti-TP antibody in a body fluid sample by an antigen-antibody reaction between the anti-TP antibody in the body fluid sample and the TP antigen mixture of the present invention. To that extent, enzyme immunoassay, immunoturbidimetry, radioimmunosy, latex agglutination or turbidimetry (hereinafter referred to as latex agglutination or turbidimetry), blood cell or particle agglutination (hereinafter referred to as blood cell or particle agglutination), immunochromatography, etc. can be used.

[0036] Enzyme immunoassay is an example of an enzyme immunoassay method. ELISA (Enzyme-Linked Immunosorbent Assay), FEIA ( Fluorescence Enzyme Immunoassay (CLEIA) (Chemiluminescent Enzyme Immunoassay), CLIA ( Examples include chemiluminescent immunoassay. Note that the abbreviation CLIA is often used to mean CLEIA.

[0037] Examples of immunoturbidimetry include nephelometry and IA (turbidimetric immunoassay).

[0038] Examples of radioimmunoassays include RIA (Radio Immunoassay) and CPBA (Competitive Protein Binding Assay).

[0039] Examples of latex agglutination and turbidimetric methods include LA (Latex Agglutination), LA (Latex Agglutination Turbidimetric Immunoassay), LPIA (Latex Photometric Immunoassay), KIMS (Kinetic Interaction of Microparticles), and Colloidal Gold Immunoassay.

[0040] Examples of hematological and particle agglutination methods include PA (Particle Agglutination Reaction). Examples include PHA (Passive Hemagglutination).

[0041] In the measurement method of the present invention, specifically, the TP antigen mixture of the present invention is applied as the TP antigen for capturing anti-TP antibodies in the body fluid sample in each of the above-described immunological measurement methods. The specific form of this application can be freely selected depending on the measurement method to be applied.

[0042] In the measurement method of the present invention, when performing an enzyme immunoassay, for example, in ELISA, the TP antigen mixture is immobilized in the wells of a 96-well plate used as the solid phase, and a body fluid sample is brought into contact with it to bind anti-TP antibodies in the body fluid sample to the TP antigen mixture immobilized in the wells. Subsequently, an anti-human antibody to which a predetermined enzyme label has been attached is brought into contact with the TP antigen mixture to which the anti-TP antibodies in the body fluid sample in the wells have been bound, and the anti-TP antibodies in the body fluid sample can be measured by the color signal obtained from the enzyme label. In other enzyme immunoassay methods, the TP antigen mixture of the present invention is immobilized on a solid phase corresponding to the respective measurement method, for example, predetermined particles, and anti-TP antibodies in the body fluid sample are brought into contact with it. An anti-human antibody labeled according to the type of measurement method is bound to the TP antigen mixture to which the anti-TP antibodies immobilized on the solid phase have been bound, and the anti-TP antibodies in the body fluid sample can be measured by the signal from the predetermined label, for example, a fluorescent substrate (FEIA), a chemiluminescent substrate (CLEIA or CLIA), etc.

[0043] When using immunoturbidimetry, the anti-TP antigen in the body fluid sample can be measured by bringing the body fluid sample into contact with the TP antigen mixture of the present invention in a liquid phase and measuring the scattering intensity (nephelometry) or transmittance (IA) of light relative to the liquid phase.

[0044] When using radioimmunoassay, for example, in RIA, a competitive antigen-antibody reaction is performed between the RI-labeled antibody and the anti-TP antibody in the body fluid sample against a certain amount of the TP antigen mixture of the present invention, and the labeled antibody bound to the antigen (bound form) and the labeled antibody not bound to the antigen are obtained. The free form of the antibody can be separated, and its proportion can be measured as the concentration of anti-TP antibody based on its radioactivity. Methods include the two-antibody method, which precipitates the antigen-antibody complex with a second antibody; the ammonium sulfate salting-out method, which precipitates with ammonium sulfate; and the PEG precipitation method. In the CPBA method, anti-TP antibodies in a body fluid sample that are not labeled with an RI compete with the reaction between the RI-labeled antibody and the TP antigen mixture of the present invention fixed to the solid phase. After this, the bound antibody and free antibody can be separated and their radioactivity can be measured.

[0045] When using the latex agglutination method or turbidimetry method, for example, the latex agglutination reaction involves sensitizing solid latex particles with the TP antigen mixture of the present invention, performing an antigen-antibody reaction between the sensitized latex particles and anti-TP antibodies in the body fluid sample, and determining the presence of anti-TP antibodies in the body fluid sample based on the presence or absence of agglutination due to the antigen-antibody reaction. The reaction is mainly carried out on a glass slide, and the resulting turbidity is observed. The latex agglutination turbidimetry method measures anti-TP antigens in a body fluid sample based on the change in turbidity of the reaction solution accompanying the agglutination of sensitized latex in the above latex agglutination reaction, and is automated. The latex near-infrared turbidimetry method measures anti-TP antigens in a body fluid sample based on the transmittance obtained by irradiating the turbidity of the reaction solution accompanying the agglutination of sensitized latex in the above latex agglutination reaction with near-infrared light. The microparticle turbidimetry method uses microparticles bound to the TP antigen mixture of the present invention as a solid phase to perform an antigen-antibody reaction with anti-TP antibodies in a body fluid sample. The turbidity of the agglutination resulting from this antigen-antibody reaction is measured from the transmittance to determine the presence of anti-TP antigen in the body fluid sample. The gold colloid immunoassay method involves reacting the anti-TP antibodies in the body fluid sample, captured by the antigen-antibody reaction with the TP antigen mixture of the present invention, with gold colloid-labeled TP antigen, and determining the presence of anti-TP antigen in the body fluid sample by the color change of the gold colloid. This principle is sometimes also used in immunochromatography.

[0046] When using the hematopoietic cell / particle agglutination method, for example, the particle agglutination reaction is a method in which an antigen-antibody reaction is carried out between anti-TP antigens in a body fluid sample and sensitized particles using gelatin particles or the like on which the TP antigen mixture of the present invention has been adsorbed (bound) to, and the presence or absence of agglutination due to this reaction is used to determine the presence or absence of anti-TP antibodies in the body fluid sample. The passive erythrocyte agglutination reaction is a method in which anti-TP antibodies in a body fluid sample are carried out using sensitized red blood cells on which the TP antigen mixture of the present invention has been immobilized on the surface of the red blood cells, and the presence or absence of agglutination due to the antigen-antibody reaction is used to determine the presence or absence of anti-TP antibodies in the body fluid sample.

[0047] Immunochromatography is an immunoassay method that utilizes the property of liquids to move along a membrane, such as a nitrocellulose membrane, due to capillary action. First, a body fluid sample is brought into contact with the labeled TP antigen mixture of the present invention to form a labeled antigen-antibody complex. As this complex moves along the membrane, it is captured by the TP antigen immobilized downstream, and the presence or absence of labeling can be used to determine the presence or absence of anti-TP antigen in the body fluid sample. It is also used as a tool for point-of-care testing (POCT). Further details will be described later.

[0048] The present invention provides the above measurement method in which a solid-phase fixed material of the TP antigen mixture is used. The solid-phase fixed material includes tubes, columns, etc. on which the above-mentioned TP antigen mixture is fixed; multi-well plates such as 96-well plates; particles such as latex particles, gelatin particles, microparticles, etc. The present invention also provides these fixed materials (hereinafter also referred to as the solid phase of the present invention).

[0049] Furthermore, the present invention provides a solid-phase region for the TP antigen mixture, A region for detecting a complex of the antigen mixture and the anti-TP antibody in the body fluid sample, which is formed by contact between the solidified region and the body fluid sample and moves through the continuous phase by capillary action mediated by the aqueous phase, is provided downstream of the solidified region. The present invention provides an immunochromatographic device for measuring Treponema pallidum (hereinafter also referred to as the device of the present invention).

[0050] (7) Method of providing data, etc. The measurement method of the present invention can also be described as a data acquisition method in which, for example, a TP antigen mixture of the present invention is brought into contact with a body fluid sample, and the anti-TP antibody in the body fluid sample is measured as a signal of binding to the TP antigen mixture, and this signal is acquired as data on the syphilis infection of the sample provider. It is.

[0051] Furthermore, the present invention provides a kit for performing the measurement method of the present invention (hereinafter also referred to as the "kit of the present invention"), which includes the solid phase of the present invention as an element. The kit of the present invention can also freely include other elements used in the measurement, such as a diluent, a labeled second antibody, and a labeled manifestation reagent, depending on the specific immunological measurement method. [Effects of the Invention]

[0052] The present invention provides a means for measuring anti-TP antibodies in body fluid samples, with measurement sensitivity that is clearly improved compared to conventional products and at a practical level. [Brief explanation of the drawing]

[0053] [Figure 1] This figure shows an example of a device used when the measurement method of the present invention is performed by immunochromatography. [Figure 2] This diagram shows an example of the measurement principle when the measurement method of the present invention is performed by immunochromatography. [Figure 3] This diagram illustrates the measurement principle when the measurement method of the present invention is performed using an enzyme immunoassay method such as ELISA. [Modes for carrying out the invention]

[0054] Embodiments of the present invention will be described with reference to the drawings.

[0055] Figure 1 is a diagram showing an example of a device used when the measurement method of the present invention is performed by immunochromatography. The immunochromatographic device 10 (hereinafter referred to as device 10) is constructed by fixing a water absorption phase 1, a mobile phase 2, and a sample drop / reaction phase 3 on a packing sheet 5, and the water absorption phase 1, mobile phase 2, and sample drop / reaction phase 3 are in contact with each other in a manner that allows water to flow between them. A color development area 21 is provided in the mobile phase 2. When a body fluid sample is dropped onto the sample drop / reaction phase 3, the anti-TP antibody in the sample reacts with the TP antigen mixture contained in the sample drop / reaction phase 3 to form an anti-TP antibody-TP antigen complex. This complex moves by capillary action in the direction of 3→2→1 and is captured in the color development area 21, which is provided with a means for capturing the anti-TP antibody-TP antigen complex and a signal color development means, thereby inducing a predetermined color development. To promote the movement by capillary action described above, a developing solution may be added separately to the sample drop / reaction phase 3, either directly or upstream thereof. Free TP antigen and developing solution are trapped in the water absorption phase 1. In addition to its trapping function, the water absorption phase 1 also plays a role in rectifying the capillary action, and a highly absorbent material such as cotton or filter paper is preferred. The predetermined color development described above serves as a signal that anti-TP antibodies are present in the body fluid sample. If color develops, anti-TP antibodies are present in the body fluid sample (positive), and if no color develops, anti-TP antibodies are not present (negative).

[0056] Figure 2 is a diagram illustrating an example of the measurement principle using device 10. The basic reaction principle in device 10 is an antigen-antibody reaction between anti-TP antibody in a body fluid sample and the TP antigen mixture of the present invention. In the sample dropping / reaction phase 3 shown in Figure 2, sensitized particles 41, which are particles 61 sensitized with "TP antigen mixture 50, which is a mixture of 15-17 antigen 52 and 47 antigen 53," are attached in a state that allows them to move by water-mediated capillary action. Examples of particles 61 include colored latex particles, fluorescent particles, and metal colloid particles such as gold colloid. Alternatively, instead of using particles 61, it is also possible to use, for example, a TP antigen mixture 50 on which a label such as a chromogenic enzyme is directly supported. In addition to gold colloid, other metal colloids such as silver colloid and selenium colloid can also be used as the metal colloid. Furthermore, the label such as a chromogenic enzyme generates a predetermined signal by reacting the chromogenic enzyme with a label-revealing reagent such as a substrate in the color development area 21. The labeling reagent can be dropped separately onto the color development area 21, but it is preferable to provide a mechanism in the color development area 21 in which, for example, the labeling reagent is pre-applied to the color development area 21, and the signal is automatically generated by the intervention of water that moves by capillary action.

[0057] As mentioned above, blood samples are preferred as bodily fluid samples that may contain anti-TP antibody 51. Examples of blood samples include whole blood samples, serum samples, and plasma samples, with serum or plasma samples being preferred. Since anti-TP antibody 51 in bodily fluid samples is an antibody produced as a humoral immune response when a subject is infected with TP, the presence of anti-TP antibody 51 in bodily fluid samples is a signal regarding the subject's syphilis infection, that is, a signal that the subject is infected with syphilis, or at least was infected with it.

[0058] The material of the sample application / reaction phase 3 is not limited as long as it is possible to adhere the sensitizing antigen 41, etc., to it during drying, and in the liquid phase of a body fluid sample, developing solvent, etc., the TP antigen in the TP antigen mixture, or the anti-TP antibody-TP antigen complex, dissociates. Examples include glass fiber, cotton, and filter paper. In addition, a sample application phase (not shown) and a reaction phase may be provided separately. In this case, the sample application phase is placed upstream of the reaction phase to which the sensitizing particles 41, etc., are attached. As described above, the developing solvent that may be added is not limited as long as it does not inhibit the antigen-antibody reaction and the 3→2→1 reaction can proceed by capillary action in the device 10, and various aqueous solvents, such as water, buffer solution, and physiological saline, are examples.

[0059] In device 10, first, the anti-TP antibody 51 in the body fluid sample comes into contact with the TP antigen mixture 50 (composed of numerous 15-17 antigens 52 and numerous 47 antigens 53) sensitized on the surface of the sensitized particles 41 attached to the sample dropping / reaction phase 3 (Figure 2(1)), and a particle 42 carrying the anti-TP antibody-TP antigen complex (complex-carrying particle 42) is formed by the antigen-antibody reaction (Figure 2(2)).

[0060] Mobile phase 2 is a material on which TP antigens in the TP antigen mixture or composite-carrying particles 42 can move by water-mediated capillary action, and is not particularly limited as long as it is a material on which a color-developing area 21 can be provided. Examples include nitrocellulose membrane, cellulose nanofiber, glass fiber, silica gel, etc. The composite-carrying particles 42 that reach the color-developing area 21 by capillary action are captured in the color-developing area 21. The capture means is integrated with the color-developing means. Specifically, the color-developing area 21 has TP antigens immobilized in a linear shape. This immobilization needs to be strong and not move or diffuse by water. Furthermore, the TP antigens immobilized in the color-developing area 21 are preferably the TP antigen mixture 50, but other TP antigens, such as native TP antigens or TP antigens transformed in a different host, may also be used. In addition, the shape may be anything other than a linear shape, such as dots or circles, and is not limited at all. The complex-carrying particles 42, which have moved by capillary action, are captured in the color-developing area 21 by an antigen-antibody reaction between the immobilized TP antigen and the anti-TP antigen 51 on the complex-carrying particles 42, forming a sandwich complex 43 consisting of "immobilized TP antigen-anti-TP antibody-TP antigen" (Figure 2(3)).

[0061] The sandwich complex 43 becomes visible by developing color in the color-developing area 21 through the intended action, thereby allowing for the measurement of the presence of anti-TP antibodies in the body fluid sample. For example, in the case of colored particles such as colored latex or gold colloid, the formation of the sandwich complex 43 in the color-developing area 21 makes the color of the latex or the red color of the gold colloid visually apparent. In the case of chromogenic enzymes such as alkaline phosphatase (ALP) or peroxidase, contact with a chromogenic substrate such as 5-bromo-4-chloro-3-indolyl-phosphate disodium salt or DAB (3,3'-diaminobenzidine tetrahydrochloride) results in the detection of the color. The condition becomes visually apparent. As described above, with the method of this device 10, if the anti-TP antibody is positive, it is highly likely that the sample provider has or has had syphilis, and if it is negative, it indicates that the person is not infected with syphilis or is in a wait-and-see state. Since syphilis requires long-term follow-up, it is possible to obtain reliable data for a definitive diagnosis of syphilis by monitoring over time using the highly sensitive and easy-to-use device 10.

[0062] Figure 3 is a diagram illustrating the measurement principle when the measurement method of the present invention is performed by an enzyme immunoassay method such as ELISA. In Figure 3, the solid phase 62 has a structure on its inner wall that allows for the antigen-antibody reaction related to the measurement method of the present invention to take place. For example, the wells of a multi-well plate such as a 96-well plate are typical, but it is not limited to this and is merely an example; other embodiments may also be used, such as a column surface, particles, or a tube. In any case, the first step is to bring the anti-TP antibody 51 in the body fluid sample into contact with the TP antigen mixture 50 fixed in the solid phase 62 to perform the antigen-antibody reaction (Figure 3(1)).

[0063] The second step involves contacting the solid-phase fixed TP mixture 50-anti-TP antibody 51 complex 501 formed in the first step with a second antibody 54, which is an anti-human antibody against the anti-TP antibody 51 on which a labeling substance such as a chromogenic enzyme is supported (Figure 3(2)).

[0064] The third step is a color development step in which a labeling reagent 55, such as a reaction substrate, is reacted with the sandwich complex 502, which is formed in the second step and consists of a solid-phase fixed TP mixture 50-anti-TP antibody 51 complex 501-second antibody, to develop color (Figure 3(3)).

[0065] By measuring the signal 56, such as color development, in this third step, the anti-TP antibody 51 in the body fluid sample can be measured. As shown in Figure 3(4), by using a calibration curve that correlates signal intensity with the amount of anti-TP antibody, it is possible to perform not only qualitative but also quantitative analysis. [Examples]

[0066] The following discloses test examples and embodiments relating to the present invention.

[0067] [Manufacturing Example 1] Purification of Recombinant TP Antigen We extracted and purified the genetically modified silkworm TP antigen using approximately 100 cocoons each produced by recombinant silkworms 47 and 15-17, which were purchased on demand from RIMUCO Co., Ltd. (Uruma City, Okinawa Prefecture). These cocoons were cut into pieces approximately 5 mm in size with scissors, immersed in PBS-1% Tritonx-100, and stirred with a stirrer at 4°C for 24 hours. Next, insoluble matter was filtered off using filter paper (Whatman) to obtain the extract. The extract was concentrated using a centrifugal concentrator (Sartorius Vivaspin 20) and gel filtered using a Sephacryl S-200HR XK50 / 60 (GE) column and Tris-HCl buffer. The antigen fraction was concentrated using a centrifugal concentrator to obtain the purified recombinant antigen. The purification results are shown in Table 1.

[0068] [Table 1]

[0069] [Reference Example 1] Reactivity comparison using ELISA In a 96-well ELISA plate (BECTON DICKINSON), the native antigen and recombinant silkworm antigens (TpN47, TpN15-17) were diluted in 10 mM phosphate buffer, dispensed at a concentration of 5 μg / mL, and 100 μL / well were added to each well. The well walls were sensitized by leaving the plates overnight at 4°C. After sensitization, the plates were blocked at 37°C for 2 hours with 10 mM phosphate buffer containing 1% bovine serum albumin, then washed and dried to prepare the sensitized ELISA plates for each antigen.

[0070] 50 μL of anti-TP antibody standard solutions (Sekisui Medical) at various concentrations were dispensed into each well and incubated at room temperature for 60 minutes. After washing with 0.05% Triton X100-10 mM phosphate buffer, 50 μL of peroxidase-labeled anti-human IgG (DAKO) was added and incubated at room temperature for 1.5 hours. After washing with 0.05% Triton X100-10 mM phosphate buffer, 50 μL of a mixed solution of hydrogen peroxide and TMB (3,3',5,5'-tetramethylbenzidine) was added and allowed to develop color for 3 minutes. After stopping the reaction, the absorbance at 450 nm was measured using a spectrophotometer. The results are shown in Table 2.

[0071] [Table 2]

[0072] [Example 1] Testing using an immunochromatographic test device (1) Fabrication of a test device The immunochromatographic device shown in Figure 1 was fabricated.

[0073] A mixed antigen stock solution was prepared by mixing equal volumes of recombinant silkworm TpN47 antigen and recombinant silkworm TpN15-17 antigen, each in a 1 mg / ml phosphate buffer solution. The concentration of each antigen in the mixed antigen stock solution was 0.5 mg / ml. One volume of this mixed antigen stock solution was added to nine volumes of latex suspension (red latex particles (Bangs Laboratory) suspended in phosphate buffer) and mixed by inversion at 4°C for 5 hours. A 1% BSA-containing solution was then added. The mixture was blocked with an acid buffer to obtain a solution containing mixed antigen-sensitized latex particles.

[0074] A conjugate pad corresponding to sample application / reaction phase 3 in device 10 of Figure 1 was prepared by uniformly coating a glass fiber sheet (Millipor) cut into small pieces with the above antigen-sensitized latex particle suspension and drying it under reduced pressure for 20 hours in a vacuum drying apparatus (hereinafter referred to as the conjugate pad). The above recombinant antigen mixture solution was applied to an immunochromatographic nitrocellulose membrane (IMMUNOPORE), corresponding to mobile phase 2 in Figure 1, using a dotting machine (BIODOT XYZ3050) to create a linear color development line corresponding to color development area 21 (hereinafter referred to as the line-coated membrane). Filter paper (Whatman) was used as the moisture absorption phase in Figure 1. The conjugate pad, coated membrane, and filter paper, cut to appropriate widths and lengths, were combined as shown in Figure 1 to prepare a test device for measurement (hereinafter referred to as the product).

[0075] When a bodily fluid sample is dropped onto a conjugate pad, the anti-TP antibodies in the sample react with the TP antigen-sensitized red latex beads contained in the conjugate pad, forming an anti-TP antibody-TP antigen-sensitized latex bead complex. This complex moves along the line-coated membrane, which is the mobile phase, and binds to the immobilized TP antigen, which is immobilized downstream as a linear colored line, forming a sandwich-type complex of immobilized TP antigen-anti-TP antibody-TP antigen-sensitized red latex beads. The development solution may or may not be used during this movement on the membrane. The presence or absence of the red line of latex beads that becomes visible as a result allows for the determination of whether the sample provider has a positive signal for syphilis. If a red line appears, the syphilis signal is positive.

[0076] (2) Comparison of test devices using recombinant silkworm antigens with commercially available test reagents This study used human serum as the body fluid sample. Furthermore, no developing solution was used for membrane transfer of the above-mentioned complex. Serum with an anti-TP antibody concentration of 18.75 mIU / mL was diluted 2-fold using serum from healthy individuals who were negative for anti-TP antibodies. These diluted serums were measured using the above-mentioned test device (this product), which uses Cerodia TPPA (Fujirebio) and recombinant silkworm antigen sensitized to red latex beads as described above. For Cerodia TPPA, the preparation was carried out according to the package insert. For this product, 100 μL of serum was dropped onto the conjugate pad, developed onto the membrane, and the presence or absence of a red line after 15 minutes was used to determine positive or negative results. The results are shown in Table 3. In Table 3, "+" indicates positive, "-" indicates negative, and "±" indicates inconclusive result.

[0077] [Table 3]

[0078] While the Serodia TPPA test yielded an inconclusive result at a 32-fold dilution (9.38 mIU / mL), this product remained positive up to a 128-fold dilution (2.34 mIU / mL). This clearly demonstrates the higher sensitivity of this product. Although Serodia TPPA, the standard method for measuring anti-TP antibodies, uses native antigens, the superiority of the recombinant silkworm-derived TP antigen mixture was nevertheless observed.

[0079] (3) Comparison with commercially available test reagents using syphilis seroconversion panel measurement As mentioned above, syphilis has a latent nature, so in order to confirm the performance of test reagents at a practical level, it is necessary to examine their effects over time, and testing using a seroconversion panel is suitable. After TP infection, the production of body fluid antibodies does not occur all at once, but gradually increases from a small amount. Therefore, highly sensitive reagents can measure body fluid antibodies from a smaller amount, thus contributing to the diagnosis of TP infection at an earlier stage after infection. The performance of reagents from this perspective can be examined by using a seroconversion panel. In other words, this can be positioned as an examination of reagent performance at a practical level.

[0080] A commercially available seroconversion panel (PSS901 / SeraCare) was measured using Espline TPAb (Fujirebio), a reagent containing an immunochromatographic device, the aforementioned Serodia TPPA, and this product. Espline TPAb is a reagent that uses recombinant E. coli antigen and includes a measurement device that allows for individual determination of TpN15-17 and TpN47, and was performed according to the prescription in the package insert. This product was performed using the same procedure as in (2) above. The results are shown in Table 4. The meaning of "+", "-", and "±" in Table 4 is the same as in Table 3.

[0081] [Table 4]

[0082] Espline TPAb Tp15-17 was inconclusive on day 45 and positive on day 48, while TpN47 was positive on day 52. ​​Serodia TPPA was positive on day 45. In contrast, this product was positive on day 31, clearly capturing anti-TP antibodies earlier than the other two methods. Generally, IgM appears in the blood around 30 days after infection, and IgG appears around 45 days later; however, this product is thought to have reacted with IgM as well. Despite the difficulty in capturing IgM when using recombinant silkworm antigens in anti-TP antibody measurement, this product, using the TP antigen mixture of the present invention, demonstrates that this is possible.

[0083] [Example 2] Testing by ELISA method Each well of a 96-well ELISA plate (BECTON DICKINSON) was filled with either the native antigen (Tokiwa Chemical) or the stock solution of the recombinant silkworm antigen (TpN47, TpN15-17) prepared in Example 1(1) (TP antigen mixture). Both solutions were diluted in 10 mM phosphate buffer, dispensed at a concentration of 5 μg / mL, and 100 μL / well were left overnight at 4°C to sensitize the plates. After sensitization, the plates were blocked at 37°C for 2 hours with 10 mM phosphate buffer containing 1% bovine serum albumin, washed, dried, and prepared as sensitized ELISA plates for each antigen.

[0084] 50 μL of anti-TP antibody standard solutions (Sekisui Medical) at various concentrations were dispensed into each well and incubated at room temperature for 60 minutes. After washing, 50 μL of peroxidase-labeled anti-human IgG (DAKO) was added and incubated at room temperature for 1.5 hours. After washing, 50 μL of a mixed solution of hydrogen peroxide and TMB (3,3',5,5'-Tetramethylbenzidine) was added and allowed to develop color for 3 minutes. After stopping the reaction with sulfuric acid solution, the absorbance at 450 nm was measured using a spectrophotometer. The results are shown in Table 5.

[0085] [Table 5]

[0086] These results demonstrate that, when using the TP antigen mixture of the present invention, anti-TP antibodies in body fluid samples can be measured with extremely high sensitivity in ELISA compared to native antigens.

[0087] Furthermore, the results from Examples 1 and 2 revealed that by using immunoassay methods, including immunochromatography and ELISA, to measure anti-TP antibodies in body fluid samples, it is possible to contribute to the earlier diagnosis of syphilis. [Explanation of symbols]

[0088] 1: Moisture absorption phase 2: Mobile phase 21: Color development area 3: Sample Dropping and Reaction Phase 10: Immunochromatographic devices 41: Sensitizing particles 42: Composite-supported particles 43,502: Sandwich complex 50:TP antigen mixture 501: Solid-phase fixed TP mixture-anti-TP antibody complex 51: Anti-TP antibody 52:15-17 antigen 53:47antigen 54:Second antibody 55: Labeling reagent 56: Signal 61: Particle 62: Solid phase

Claims

1. A method for measuring antibodies in body fluids, comprising contacting a blood sample (excluding serum samples) with a mixture of recombinant TpN47 antigen derived from the cocoon filaments or silk gland of a genetically modified silkworm transformed with the TpN47 gene, which is an artificial surface antigen of Treponema pallidum, and recombinant TpN15-TpN17 fusion antigen derived from the cocoon filaments or silk gland of a genetically modified silkworm transformed with a fusion gene of the TpN15 gene and the TpN17 gene, and measuring anti-Treponema pallidum antibodies in the blood sample by an immunological measurement method as a binding signal with the mixture of antigens.

2. The method according to claim 1 , wherein the immunological measurement method is an enzyme immunoassay, an immunoturbidimetric method, a radioimmunoassay, a latex agglutination or turbidimetric method, a hemocyte or particle agglutination method, or an immunochromatography method.

3. The method according to claim 1 or 2, wherein a solid phase fixation of the mixture of the recombinant TpN47 antigen and the recombinant TPN15-TPN17 fusion antigen is used.

4. A solid phase on which an antigen is immobilized, the solid phase being used for measuring anti-Treponema pallidum antibodies in a blood sample (excluding serum samples), the solid phase having a mixture of recombinant TpN47 antigen derived from the cocoon filaments or silk gland of a genetically modified silkworm transformed with the TpN47 gene, which are artificial surface antigens of Treponema pallidum, and recombinant TpN15-TpN17 fusion antigen derived from the cocoon filaments or silk gland of a genetically modified silkworm transformed with a fusion gene of the TpN15 gene and the TpN17 gene.

5. The solid-phase region is provided with a mixture of a recombinant TpN47 antigen derived from the cocoon filaments or silk gland of a recombinant silkworm transformed with the TpN47 gene, which is an artificial surface antigen of Treponema pallidum, and a recombinant TpN15-TpN17 fusion antigen derived from the cocoon filaments or silk gland of a recombinant silkworm transformed with a fusion gene of the TpN15 gene and the TpN17 gene; a detection region for detecting a complex between the mixture of antigens and an anti-Treponema pallidum antibody in a blood sample, the complex being formed by contact between the solid-phase region and the blood sample (excluding a serum sample) and moving in a continuous phase by capillary action mediated by an aqueous phase, is provided downstream of the solid-phase region; Immunochromatographic device for measuring Treponema pallidum.